Lidokain Mylan

Lidocaine, the active ingredient in Lidokain Mylan, is a local anesthetic presented as an injectable solution for intravenous use. Approved in the European Union, it provides rapid local and regional anesthesia and is also utilized in the treatment of ventricular arrhythmias under cardiac monitoring.

GNH USA supplies Lidokain Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, providing consistent quality, regulatory compliance and reliable logistics for global healthcare providers.

Lidokain Mylan is used in clinical situations that require local or regional nerve block or intravenous anti‑arrhythmic therapy.

- Local anesthesia: provides reversible loss of sensation for minor surgical or diagnostic procedures. - Regional anesthesia: enables nerve block techniques for limb or trunk surgeries, offering targeted analgesia. - Ventricular arrhythmias: administered intravenously to suppress ventricular ectopic activity during acute cardiac events.

Adverse reactions to lidocaine injection can range from mild, transient events to rare but serious complications.

Common Side Effects: - Tingling or numbness at the injection site. - Light‑headedness or dizziness. - Nausea or vomiting. - Metallic taste in the mouth. - Transient visual disturbances. - Mild hypotension.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with rash, bronchospasm, or angioedema. - Cardiac conduction disturbances such as bradycardia, heart block, or ventricular arrhythmias. - Central nervous system toxicity presenting as seizures, confusion, or loss of consciousness. - Persistent hypotension or cardiovascular collapse. - Methemoglobinemia leading to cyanosis and hypoxia.

When using Lidokain Mylan, clinicians should observe specific safety measures to minimize risk.

- Patient assessment: evaluate cardiac history, liver function and allergy status before administration. - Dose adjustment: reduce dose in patients with hepatic impairment or advanced age. - Monitoring: continuously monitor ECG and blood pressure during intravenous infusion. - Concomitant drugs: avoid simultaneous use with other class I anti‑arrhythmics or high‑dose beta‑blockers without supervision. - Resuscitation readiness: have emergency airway and cardiovascular support equipment available. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Lidokain Mylan may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I anti‑arrhythmic agents (e.g., quinidine, procainamide): additive cardiac conduction effects. - Beta‑blockers (e.g., propranolol) in high doses: increased risk of bradycardia and hypotension. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma lidocaine levels.

Moderate Interactions (Monitor Closely): - Other local anesthetics (e.g., bupivacaine): cumulative neuro‑ and cardiotoxicity. - Diuretics (e.g., furosemide): may enhance lidocaine plasma concentration. - Anticonvulsants (e.g., phenytoin): potential alteration of seizure threshold.